Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide in Advanced HCC
NCT00396682Phase 3Completed
- Sponsor
- Hannover Medical School
- Start
- Feb 2007
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of cyclophosphamide in hepatocellular carcinoma (HCC), sponsored by Hannover Medical School. Primary endpoints: Frequency of CD4+CD25+ regulatory T cells at 8 weeks and Tumor specific immune responses at 12 weeks. Started Feb 2007; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00396682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00396682.